ホワイトペーパー

Dr. Reddy’s is among the earliest generic API manufacturers globally for Rivaroxaban API and filed the USDMF in March 2014. 

Dr. Reddy’s process involves a selective and efficient chemical transformations that offer distinctive advantage for quality and manufacturability. The process eliminates the potential impurities formed in the process, and can be robust and safely operated at a commercial scale.

In selected markets, we can also provide the formulated drug product of Rivaroxaban and will support you in all regulatory aspects from filing to registration.

To know more about our Rivaroxaban offerings, read the tech sheet by filling the contact form below.